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1. Introduction 
Barrett’s esophagus (BE) represents a metaplastic change from squamous epithelium to 
intestinal epithelium as a result of chronic gastroesophagheal reflux. Since the development 
of esophageal adenocarcinoma (EAC) is not universal among patients with BE, it is 
important to understand and to gauge the factors that influence risk of progression to 
dysplasia and cancer. While heartburn symptoms have been reported to be associated with 
BE (Eisen et al., 1997; Lagergren et al., 1999a), the severity of gastroesophageal reflux 
symptoms is not a reliable indicator for the presence of BE (Eloubeidi and Provenzale, 2001). 
There is a vital need to explore factors other than symptoms that not only may elucidate the 
pathophysiology of BE development but also that may be predictive of progression to EAC. 
Significant advances have been made along key areas such as cell cycle abnormalities, 
growth factors, adiposity, and the gut microbiome. This chapter aims to review some of 
these elements as well as the prognostic value of biomarkers for progression from BE to 
EAC. The importance of fulfilling the promise that these biomarkers hold is underscored by 
the notable increase in the risk of progression to cancer from 0.5% per year in non-dysplastic 
BE, to 13% in the setting of low-grade dysplasia, and to 40% in high-grade dysplasia 
(Curvers et al., 2010; Wani et al., 2009). 
2. Cell cycle abnormalities 
The normal cell cycle by which cells proliferate is comprised of an intricate system of 
checkpoints and regulations designed to carefully modulate growth. Cell cycle regulation is 
dependent on the members of several protein classes, including cyclins and cyclin 
dependent kinase (CDK) complexes, tumor suppressors, and pro as well as anti-apoptotic 
proteins. Derangements in this system result in dysregulation of the cell cycle and provide 
opportunity for uncontrolled proliferation, as well as the potential for neoplastic 
progression (Evan and Vousden, 2001). The tissue invasion and metastatic progression 
phases of the neoplastic change are also dependent on cellular as well as extracellular 
proteins that are normally involved in cell cycle regulation. The pathophysiologic 
mechanisms through which these proteins function have been implicated in most cancers 
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and are the focus of current research due to their possible prognostic value and implication 
for therapeutic targeting. The association of chronic GERD with the development of BE, 
dysplasia, and EAC (Gerdes, 1990; Herbst et al., 1978; Pellish et al., 1980; Preston-Martin et 
al., 1990; Reid et al., 1993; Ronkainen et al., 2005) provides an opportunity to explore the 
underlying cellular mechanisms that drive the transformation. This section will discuss the 
mechanisms by which cell cycle proteins may confer a survival advantage for 
transformation of BE to EAC.  
As a class, tumor suppressor genes code for proteins that protect the cell by arresting the 
cellular growth cycle or by promoting apoptosis. Proteins such as p53, p16, and 
adenomatous polyposis coli (APC), normally recognize DNA damage and halt progression 
through the cell cycle, allowing for repair, senescence, or cell death. Therefore allelic 
mutations leading to loss of function of these proteins can be carcinogenic (Sherr, 2004). 
Mutations of the p53 protein have been implicated in nearly every cancer and may be one of 
the most common derangements in BE and EAC (Greenblatt et al., 1994; Vaninetti et al., 
2008). Normally the detection of DNA damage results in p53 activation via signals that 
promote p21 transcription with subsequent binding and inhibition of cyclin dependent 
kinase-complexes that prevent progression into the next stage of the cell cycle (Levine, 
1997). Additionally p53 triggers apoptosis through the intrinsic pathway mediated by Bax 
and Bak as well as the extrinsic pathway via Fas action. Through different downstream 
pathways these proteins lead to the release of cytochrome C and other intermitochrondrial 
proteins into the cytosol including caspace formation, leading to cellular degradation 
(Levine, 1997; Levine et al., 2006; Petros et al., 2004; Vousden, 2005). Mutated p53 has a 
prolonged half-life and its overexpression can be detected as deposits in the cell nucleus 
(Hinds et al., 1990). Without normal p53 regulation damaged cells are no longer inhibited 
from progressing through the cell cycle and are not marked for repair, senescence, or 
apoptosis. Furthermore the damaged DNA leads to additional genetic mutations that 
perpetuate cancerous gene formation as well as cells that are resistant to treatment. Several 
studies have found overexpression of p53 throughout the different stages of carcinogenesis 
to be a risk factor for progression from BE to EAC, however the exact mechanism has not 
been completely elucidated (Krishnadath et al., 1995; Murray et al., 2006; Ramel et al., 1992). 
As a clinical prognostic indicator alterations in p53 expression have been found to be 
predictive of response to chemotherapy and overall survival (Heeren et al., 2004; Madani et 
al., 2010). 
P16, the protein product of the INK4A/CDKN2A gene, is a cyclin dependent kinase 
inhibitor that has been demonstrated to be mutated in a variety of cancers including EAC. 
P16 tumor suppression is initiated by cellular stress leading to the binding of p16 to CDK4 
and CDK6. CDK4/p16 and CDK6/p16 complexes inhibit formation CDK-cyclin D 
complexes, leading to the destruction of cyclin D (Diehl and Sherr, 1997; Rocco and 
Sidransky, 2001). Without cyclin D, p27KIPI accumulation occurs, which in turn prevents 
CDK2/cyclin E and CDK2/cyclin A complexes from phosphorylating the retinoblastoma 
protein (Rb). The Rb protein is required for activation of the transcriptional complex E2F-DB 
and subsequent gene transcription. Additionally the Rb-E2F complexes that form serve as 
inhibitors of transcription. Given this series of steps, proper p16 regulation responds to cell 
stress by inhibiting transcription, which is required for the cell to continue through the G1/S 
cell cycle checkpoint (Rocco and Sidransky, 2001). Mutation in p16 genes, occur through 
point mutations, loss of heterozygosity, and/or silencing of the gene through promoter 
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hypermethylation (Maley et al., 2004; Rocco and Sidransky, 2001). Therefore, loss of p16 
activity in the context of DNA damage and cellular stressors, permit the cell to undergo 
unregulated transcription and proliferation. There exists an increasing amount of evidence 
showing that p16 inactivation is a critical step in the development of EAC. In fact the most 
prevalent genetic alteration in BE is the result of INK4A/CDKN2A hypermethylation, 
which is an early epigenetic change that occurs in the progression from BE to EAC (Bian et 
al., 2002; Hardie et al., 2005; Powell et al., 2005; Souza et al., 2001; Vieth et al., 2004).  
As a tumor suppressor, the adenomatous polyposis coli (APC) protein has been implicated in 
the development of EAC (Clement et al., 2006a, b). APC is part of the Wnt signaling pathway 
which modulates the levels of β-catenin, a key protein for cell-cell adhesion and transcription. 
This pathway is activated by Wnt proteins binding to receptors of the Frizzled transmembrane 
protein family and LDL-receptor-related protein, which in turn trigger the phosphorylation of 
Dishevelled protein. The Dishevelled protein blocks the phosphorylating activity of GSK3β, 
which is a complex composed of APC, Axin and casein kinase 1 (CK1). When activated, 
GSK3β phosphorylates β-catenin initiating its destruction. When β-catenin is in its 
unphosphorylated state it translocates to the cell nucleus, binds to DNA-binding proteins 
TCF/LEF, and activates gene transcription of growth promoting genes myc, COX-2, 
matrilysin/matrix metalloproteinase 7, and cyclin D (Clement et al., 2006a; Giles et al., 2003; 
Logan and Nusse, 2004; Rocco and Sidransky, 2001). Therefore loss of APC, as implicated in a 
number of cancers, may result in increased β-catenin in the nucleus and uncontrolled cellular 
proliferation and tumorigensis (Bian et al., 2000; Clement et al., 2006a; Logan and Nusse, 2004; 
Trigg, 1998). Furthermore, it has been demonstrated that APC is involved with microtubule 
function. Without functional APC there is an increase in abnormal mitotic spindles and 
subsequently chromosomal defects. Several studies have demonstrated that APC inactivation 
leads to β-catenin accumulation in EAC, but is not necessary or sufficient for activation of the 
Wnt pathway since β-catenin accumulates without APC inactivation (Clement et al., 2006a). 
Despite this patients with APC gene hypermethylation in BE samples were more likely to 
progress to EAC and several studies have shown that all EACs have APC promoter 
methylation (Wang et al., 2009b). Therefore while the exact mechanism by which loss of APC 
leads to EAC has not been completely elucidated, its detection might provide prognostic value 
in assessing the progression from BE to EAC.  
Cyclins and cyclin dependent kinases (CDKs) are integral parts of the cell cycle regulation 
control system. Cyclins bind to CDKs and lead to phosphorylation of proteins necessary for 
progression through the cell cycle (Stamatakos et al., 2010). In addition to these regulators, 
p21 acts as a cyclin dependent kinase inhibitor in tumor suppression as well as a possible 
oncogene, inhibiting apoptosis and promoting proliferation (Abbas and Dutta, 2009; Gartel, 
2006). Derangements in the function of these proteins have been implicated in nearly all 
tumors and their involvement in the progression to BE and EAC is an area of active 
investigation. Cyclin D1 regulates cell cycle activity by forming a complex with CDK4/6 
and controlling activity through G1. Once bound, cyclin D1/CDK 4/6 complexes 
phosphorylate the retinoblastoma protein (Rb), deactivating it and activating E2F 
transcription complex. E2F leads to the transcription of genes required for transition 
through G1 (Shapiro and Harper, 1999; Traganos, 2004). One of the genes transcribed when 
E2F is activated, cyclin E binds CDK2 leading to phosphorylation of downstream targets 
that are necessary for replication initiation, histone synthesis, and replication of 
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centrosomes. This allows transition through G1 checkpoint to the S phase (Ma et al., 2000). 
Additionally, cyclin E/CDK2 complexes further phosphorylate Rb leading to additional 
transcriptional activity (Fu et al., 2004). P21 has been described initially in the tumor 
suppression cascade of p53 as described above, however new research suggests that it may 
also have the opposite action as an oncogene promoting tumorinogensis (Gartel, 2006). 
Cyclin D1 has been implicated in a number of cancers and is overexpressed due to 
derangements that include chromosomal translocations, gene amplification and anomalies 
in proper intercellular trafficking and proteolysis (Kim and Diehl, 2009; Stamatakos et al., 
2010). When overexpressed cyclin D1 leads to tumor formation through several 
mechanisms. First, high levels of cyclin D1 lead to increased activation of CDK4/6 leading 
to increased proliferation. Second, cyclin D1/CDK complexes inhibit p21 and p27 activity, 
two CDK inhibitors, and therefore with abnormal levels of p21/p27 inhibition there is 
decreased inhibitory control over the cell cycle (Cheng et al., 1998). Third cyclin D1 also has 
non-CDK dependent actions including increasing estrogen receptor transcription (Neuman 
et al., 1997) as well as abnormalities in the repression of PPARγ, a transcriptional protein 
modulated by abnormal binding of HDAC by cyclin D1 (Fu et al., 2005). In addition cyclin 
D1 has been reported to lead to increased expression of fibroblast growth factor 1 (Tashiro et 
al., 2007) as well as increased production of reactive oxygen species (ROS) leading to 
metastasis of tumors (Stamatakos et al., 2010). Although the exact mechanism of action in 
EAC has not been completely elucidated, studies have demonstrated cyclin D1 
overexpression in BE and early stages of tumorigensis (Arber et al., 1996; Bani-Hani et al., 
2000).  
Aberration in cyclin E activity, from gene amplification (Marone et al., 1998; Stamatakos et 
al., 2010) or defective degradation (Buckley et al., 1993), leads to constitutive expression and 
increased activity of the protein, which results in increased cellular proliferation 
(Stamatakos et al., 2010). Increased levels of cyclin E lead to increased activity of CDK2, 
subsequent activation of transcription proteins, as well as increased phosphorylation of Rb. 
Given the pathway described above, these anomalies may all lead to deregulated 
progression into the S phase and consequently amplified proliferation. This has been noted 
as a shortened G1 phase, decreased cell size due to decreased time for growth, and 
decreased requirement for proper environmental factors necessary for replication (Sala et 
al., 1997; Stamatakos et al., 2010). The relevance of cyclin E and its deregulation in the 
development of EAC is currently unclear.  
Although P21, a cyclin dependent kinase inhibitor, was thought to solely act in the tumor 
suppression cascade of p53 as described above, recent evidence suggests that it also has the 
opposite role as an oncogene, inhibiting apoptosis and promoting cellular proliferation 
(Abbas and Dutta, 2009; Gartel, 2006; Roninson, 2002). In the tumor suppression cascade of 
p53, loss of p21 inhibition of cyclin-CDK complexes, especially CDK2, in cells with DNA 
damage may lead to uncontrolled progression through the cell cycle and carcinogenesis 
(Abbas and Dutta, 2009). Additionally, it is hypothesized that p21 contains antiapoptotic 
activity and therefore, when overexpressed, damaged cells avoid degradation and 
proliferate to form tumors (Roninson, 2002). P21 might also promote cyclin D1 accumulation 
in the nucleus, therefore avoiding destruction, and facilitating binding with CDK4/6, 
leading to increased transcription (LaBaer et al., 1997; Liu et al., 2007). P21 has not been 
extensively studied in BE and EAC, but some evidence suggests that similar to p53 changes 
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in the expression pattern of p21 may lead to a better response to treatment in these patients 
(Heeren et al., 2004).  
In addition to the main regulatory proteins described above, several other proteins have 
been implicated in carcinogenesis and may have a role in BE and EAC. Apoptosis is a key 
component of normal cellular functioning that serves to limit cells with DNA damage by 
triggering them to self destruct. Two proteins have been implicated in cells evading proper 
apoptotic pathways, cyclooxygenase 2 (COX-2) and B cell lymphoma 2 protein.  
While COX-2 is not constitutively expressed in all tissues, it is found in response to 
inflammation or mitogenic stimuli ultimately leading to increased production of 
prostaglandins (PGs) (Konturek et al., 2005). Recent evidence has demonstrated that COX-2 
expression increases with worsening grades of dysplasia in esophageal carcinogenesis 
(Cheong et al., 2003; Konturek et al., 2004) and that the increased COX-2 expression in the 
esophageal epithelium might be secondary to gastric acid and bile exposure (Shirvani et al., 
2000). The mechanisms by which COX-2 overexpression leads to the development of EAC is 
related to COX-2 derived PGs’ actions. These prostaglandins are involved in evasion of 
apoptosis by inhibiting release of cytochrome c, decreasing activation of caspase-9 and -3, 
increasing activity of bcl-2 (Wang et al., 2005) and blocking Fas mediated cell death (Nzeako 
et al., 2002). BE cells with overexpression of COX-2 have lower rates of apoptosis (Wilson et 
al., 1998). Additionally, COX-2 produced PGs have been implicated in invasion and 
metastasis, theorized to be due to increased metalloproteinase-2 activity (Nzeako et al., 
2002). Furthermore, COX-2 derived PGs have been demonstrated to lead to cell proliferation 
through stimulation of epidermal growth factor receptors (Baatar et al., 2002), angiogenesis 
by increasing VEGF levels (Wang and DuBois, 2004); (Shiff et al., 2003) and inhibition of 
immune anti-tumor responses by hampering the activity of natural killer cells, 
macrophages, and dendritic cells, and decreasing production of Th1 cytokines. Given these 
mechanisms, it is not surprising that multiple studies have demonstrated a decreased risk of 
progression to cancer (Buttar et al., 2002), and decreased cell proliferation in BE epithelium 
when treated with COX inhibitors (Kaur et al., 2002).  
B cell lymphoma 2 protein (Bcl-2) is an integral part in regulation of cell survival by 
inhibiting apoptosis. Overexpression of Bcl-2 has been documented in a number of cancers 
as well as all phases of reflux-associated esophageal carcinogenesis including esophagitis, 
nondysplastic BE, dysplatic BE, and EAC (Metzger et al., 2004). Overexpression of Bcl-2 
leads to inhibition of apoptosis early in carcinogenesis leading to decreased cell death and 
elongated cell lifespan (Metzger et al., 2004) (Lehrbach et al., 2009) (Thomadaki and Scorilas, 
2006). The extended cell survival is hypothesized to allow for accumulation of oncogenic 
mutations leading to carcinogenesis (Zhivotovsky and Orrenius, 2006). Bcl-2 overexpression 
leads to apoptotic evasion by inhibiting mitochondrial release of cytochrome c and eventual 
caspase formation (Thomadaki and Scorilas, 2006). In fact, cells with elevated Bcl-2 
production are more resistant to chemotherapy and radiation treatment (Thomadaki and 
Scorilas, 2006). However, its exact role in EAC development has not been extensively 
studied.  
In order for tumors to survive, invade, and metastasize there are a number of proteins 
involved including Tissue inhibitors of metalloproteinase (TIMPs). These classes of proteins 
have distinct roles in this aspect of tumorigenesis and have been associated with BE and 
EAC. 
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TIMPs are enzymes that regulate the production and actions of metalloproteinases (MMPs), 
which are responsible for turnover and remodeling of the extracellular matrix and cell 
signaling, in addition to non-MMP dependent actions. TIMPs have been evaluated in a 
number of cancers and have demonstrated multi-factorial and contradictory roles in cancer, 
with both overexpression and silencing observed. Furthermore, it is theorized that TIMPs 
exhibit different actions depending on the level of expression. Mechanisms by which TIMPs 
are involved in carcinogenesis include apoptosis and cell proliferation, angiogenesis, and 
metastasis and cell adhesion (Bourboulia and Stetler-Stevenson, 2010; Cruz-Munoz and 
Khokha, 2008; Jiang et al., 2002; Sun, 2010). In cancer cell lines, TIMP-1 enhanced cell 
survival and growth by increasing expression of IL-10 and anti-apoptotic protein bcl-xl 
(Chirco et al., 2006). TIMPs promote cell proliferation by increasing p65 phosphorylation, 
which increases NF-Kβ, a protein that binds gene promoters and leads to cell proliferation. 
This, however, was observed at late stages of tumor growth while upregulation of NF-Kβ 
has also demonstrated slowing tumor growth in its early stages. The exact role in 
proliferation seems to depend on the stage of tumorigenesis (Sun, 2010). TIMPs are thought 
to enhance angiogenesis by increasing vascular endothelial growth factor (VEGF) 
production and inhibiting MMPs, which, produce angiogenesis inhibitors, endostatin and 
angiostatin (Jiang et al., 2002). As well, TIMP-2, which normally blocks microvascular 
endothelial cell growth in response to pro-angiogenic factors like FGF-2 or VEGF A is 
silenced through promoter hypermethylation in a number of cancers (Sun, 2010). Lastly, 
TIMPs normally inhibit cell adhesion and metastasis by blocking the breakdown of the 
extracellular matrix through inhibition of MMPs. However, in cancers there is a disruption 
of the balance between MMPs and TIMPs, with possible elevated levels of MMPs and 
increased disruption of the ECM and cell-cell adhesion leading to increased cell motility 
(Bourboulia and Stetler-Stevenson, 2010; Cruz-Munoz and Khokha, 2008). Given these 
mechanisms in a number of cancer, the exact role of TIMPs in esophageal adenocarcinoma 
development from BE has not been elucidated. 
Lastly the plasmingonen acitvating system, which includes urokinase-type plasminogen 
activator (uPA), has been investigated for its prognostic value in BE. In normal physiologic 
states, this system regulates the fibrinoylitic system, however it has been implicated in a 
variety of pathologic states including tumor cell proliferation, apoptosis, cell migration and 
invasion, and angiogenesis (Laufs et al., 2006; McMahon and Kwaan, 2008). uPA, a serine 
protease has been demonstrated to be expressed in tumor cells, and is considered the most 
active component of this system. uPA is involved in cell proliferation, apoptosis, and 
angiogenesis through interaction with its cellular receptor uPAR and the epidermal growth 
factor receptor (EGFR), which stimulates cell growth through a cascade of intracellular 
mechanisms (McMahon and Kwaan, 2008). uPA is believed to assist in tumor cell migration 
and invasion by converting plasminogen to plasmin, which activates MMPs, which degrade 
ECM elements such as vitronectin, laminin, and type IV collagen, leading to altered cell 
adhesion, shape, and migration (Laufs et al., 2006; McMahon and Kwaan, 2008). 
Angiogenesis is altered by uPA by affecting endothelial cell proliferation leading to 
angiogenesis and by activating kringle structures, which inhibit microvascular endothelial 
cell proliferation through changes in angiostatin levels therefore inhibiting angiogenesis.  
Several proteins have been implicated in tumorogenesis and may have prognostic 
implications in EAC including cadherins and Ki-67. The mechanism by which these proteins 
promote oncogenesis, provide opportunity for further investigation. 
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3. Growth factors 
The mechanisms that promote evolution of BE to EAC are largely unknown. As 
derangements in the cell cycle are believed to be involved in carcinogenesis and the 
development of uncontrolled cellular replication, growth factors have been the focus of 
investigations in the neoplastic progression of BE. Three such factors that have been 
recognized as promoting growth in BE are: epidermal growth factor (EGF), vascular 
endothelial growth factor (VEGF), and transforming growth factor beta (TGF-ǃ). 
The epidermal growth factor receptor (EGFR) family of receptors has been studied as a 
potential biomarker in the progression of BE to EAC. This family of tyrosine kinase 
receptors initiates a signal transduction cascade that modulates cell proliferation, 
differentiation, adhesion, and migration (Yarden, 2001). EGFR is a transmembrane receptor 
that enables signals to be transmitted across the plasma membrane, affecting gene 
expression and a multitude of cellular responses. Overexpression of this receptor has been 
shown to occur in several malignancies, including EAC (Wang et al., 2007). 
The correlation of EGFR expression with early neoplastic progression of BE has not been 
completely elucidated. Using PCR to evaluate gene expression, amplification of the EGFR 
locus was demonstrated in EAC without concomitant elevated expression in high-grade 
dysplasia with BE (Miller et al., 2003). However, another study did show gene locus 
amplification of EGFR in both BE associated high-grade dysplasia and EAC (Rygiel et al., 
2008). There is also the possibility of a certain EGF polymorphism leading to an increased 
risk of EAC, as the specific EGFA61G G/G genotype has been shown to confer such a risk 
(Lanuti et al., 2008). 
While there is evidence linking EGFR gene expression with EAC, until recently there was 
only limited evidence of this expression in regards to protein abundance (Li et al., 2006; 
Wilkinson et al., 2004). Importantly, for EGFR to be considered a useful biomarker of 
histological progression of BE, it would increase in progression during neoplastic 
transformation. In addition, it would also be expressed on the luminal epithelial surface so 
as to be readily visualized during endoscopy, and be available for biopsy targeting. One 
recent study evaluated this potential dual role for EGFR using tissue microarray technology, 
exploring the possibility of EGFR as a relevant biomarker to monitor histological 
progression, and ultimately to allow for biopsy targeting of abnormal tissue (Cronin et al., 
2011). The study showed a stepwise increase in EGFR abundance in BE, high-grade 
dysplasia, and EAC. As EGFR is a transmembrane protein expressed on the luminal 
esophageal surface, it also has potential for sampling during endoscopy. 
VEGF is another growth marker that performs an important role in tumor formation. 
Increased vascularity is associated with a poor prognosis in several human malignancies, 
and VEGF is important for angiogenesis in neoplastic progression. By using 
immunohistochemistry to examine VEGF expression, one study specifically studied 
vascularization in both BE and associated EAC (Couvelard et al., 2000). An increase in 
angiogenesis was found in precancerous lesions, and VEGF expression correlated with the 
increase in vascularization. However VEGF in the study had no prognostic significance. 
As it is accepted that BE develops from esophageal mucosal injury incurred after acid and 
bile reflux, a study looked at VEGF expression in a bile acid environment. By quantitative 
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PCR, VEGF expression to increased after exposure to certain bile acids (Burnat et al., 2007). 
Another study looked at the possibility of an “angiogenic switch” in the transition from 
metaplasia to dysplasia to carcinoma in BE (Mobius et al., 2003). This study showed that 
VEGF expression increased during the sequence of metaplasia to advanced carcinoma. More 
specifically, the data suggested that the related impact on neovascularization occurred early 
on in the course of this transformation, as the only true significant difference in VEGF 
expression occurred between Barrett’s metaplasia and high-grade dysplasia. This entailed 
that the importance of VEGF and related angiogenesis in the progression to EAC may occur 
before actual tumor growth. 
TGF-ǃ is a growth factor predominantly involved in cellular proliferation and differentiation, 
and several studies suggest that loss of TGF-ǃ signaling is an important factor in BE-related 
EAC. Smad4, a protein that is part of a TGF-ǃ mediated complex important in downstream 
gene activation, has been shown to potentially have a dual importance in the neoplastic 
progression of BE. In response to TGF-ǃ, a majority of EAC cell lines in one study failed to 
growth arrest, and specific modulation of Smad4 was inhibited. However, the cell lines also 
upgraded the expression of certain proteases that led to a more invasive cell phenotype, 
suggesting a dual role for TGF-ǃ (Onwuegbusi et al., 2007). By PCR, FISH, and sequencing, 
Smad4 expression has also been shown to be progressively reduced in the metaplasia to 
dysplasia to adenocarcinoma sequence (Onwuegbusi et al., 2006).  
Other evidence propose additional roles for the downstream TGF-ǃ pathway and its 
importance in the neoplastic progression of BE. One study showed that hypermethylation 
and inactivation of RUNX3, a target gene of TGF-ǃ, is associated with the progression of BE 
to dysplasia and ultimately adenocarcinoma (Schulmann et al., 2005). TGF-ǃ also has known 
significance in the epithelial to mesenchymal transition, which promotes cellular motility, 
invasion, and cytoskeletal rearrangement in a range of tumor cells. One study looked 
specifically at the ability of TGF-ǃ to induce esophageal to mesenchymal transition in 
esophageal cell lines in vitro. The data from this study suggested a role for this transition in 
EAC, as TGF-ǃ induced alterations in aggregation and invasion, and thus a more invasive 
phenotype (Rees et al., 2006). 
There has been clear value in the investigation of EGF, VEGF, and TGF-ǃ as performing 
critical roles in the progression of BE to EAC. More examination is needed to clarify the 
independent function of these growth factors and their downstream proteins in the 
progression of this disease.  
4. Adiposity and adipokines 
Obesity, as defined by a body mass index (BMI) >30, has been increasing steadily over the 
past twenty years and has become an epidemic in the US. In 1989 the prevalence of obesity 
among adults did not surpass 15% in any state. By contrast in 2009, the prevalence of obesity 
among adults is greater than 15% in every state [Ref: http://www.cdc.gov/ 
obesity/data/trends.html#State]. It is estimated that 68% of adults twenty years of age or 
older in the US are either overweight or obese and nearly 34% of these are obese (Flegal et 
al., 2010). Obesity is associated not only with metabolic disorders such as diabetes (Bray, 
1992; Pontiroli and Galli, 1998; Scott et al., 1997) but also with neoplastic conditions such as 
EAC (Chow et al., 1998; Dvoyrin et al., 2011; Lagergren et al., 1999b). Elucidating the 
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biomolecular mechanisms that link adiposity with the development of GERD, BE, and EAC 
is an active area of investigation. Such information could provide novel targets for the 
treatment of conditions along the GERD spectrum.  
Increased adiposity, defined by BMI or waist circumference, has been shown to be an 
independent risk factor for GERD epidemiologically, while being consistently linked to 
reflux symptoms as well as mucosal injury (Hampel et al., 2005). Increasing BMI and waist 
circumference separately lead to an increased frequency of GERD symptoms, esophageal 
acid exposure, (El-Serag et al., 2007; El-Serag et al., 2005; Locke et al., 1999; Murray et al., 
2003) and reflux related hospitalizations (Ruhl and Everhart, 1999). In fact, those with a BMI 
greater than 30 kg/m2 have been shown to be approximately three times more likely to 
develop GERD symptoms at least once per week (Locke et al., 1999; Murray et al., 2003). 
Even among those who are morbidly obese, those with a higher BMI have a higher 
percentage of time during which the esophageal pH is less than four (Fisher et al., 1999).  
Obesity has also been linked to complications of GERD including the development of BE 
and EAC. These develop due to an imbalance between injurious elements and esophageal 
protective mechanisms (Vaezi and Richter, 1996). It is estimated that obesity leads to a two 
and a half fold increased risk of BE. Furthermore Stein and colleagues concluded that for 
every 10-pound increase in weight the risk of BE increases by 10%, and for each five point 
increase in BMI the risk increases by 35% (Stein et al., 2005). Recent evidence also suggests 
that abdominal obesity, specifically visceral fat, is a stronger risk factor for BE than BMI 
(Corley et al., 2007; Edelstein et al., 2007). In terms of EAC, a linear relationship with obesity 
seems to exists as higher BMI levels are associated with an increased risk of the malignancy 
(Brown et al., 1995; Chow et al., 1998; Lagergren et al., 1999b; Wu et al., 2001).  
Several mechanisms have been proposed to explain the association between the level of 
adiposity and the development of GERD. The “transmitted pressure” hypothesis suggests 
that direct mechanical pressure from the large abdominal panus can lead to an increased 
intragastric pressure, which when relayed to the lower esophageal sphincter, can result in 
reflux by way of non-swallow induced transient relaxation (El-Serag, 2008; El-Serag et al., 
2006; Lambert et al., 2005; Mercer et al., 1985; Pandolfino et al., 2006). Pandolfino et al. 
demonstrated a multi-faceted mechanism by which fat, especially visceral adiposity, leads to 
reflux. Utilizing high-resolution manometry, this study demonstrated that for every inch of 
increased waist circumference, there is a significant increase in intragastric and 
intraesophageal pressures, 0.4 mm Hg and 0.1 mm Hg, respectively. Additionally both the 
mean gastroesophageal pressure gradient (GEPG) as well as the disruption of the 
esophagogastric junction (EGJ), measured as separation of the lower esophageal sphincter 
and extrinsic crural diagphram, were higher among obese patients. Furthermore, EGJ 
disruption allows for the development of a hiatal hernia. Finally, patients with GERD 
symptoms when compared to non-GERD patients had increased GEPG and EGJ disruption. 
Given these pressure morphologies among overweight and obese patients, it appears that 
increasing panus size creates a pathophysiologic mechanism allowing for the flow of gastric 
contents into the esophagus (Pandolfino et al., 2006). 
As an active endocrine organ, adipose tissue is also important metabolically, and produces 
adipocytokines such as leptin, and adiponectin. In addition while the gastric epithelium 
produces acid, it is also the primary source for the adipokine ghrelin. Evidence suggests that 
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these hormones are associated mechanistically in the development of BE and esophageal 
adenocarcinoma. 
Leptin, a proteohormone produced mostly in proportion to the amount of white adipose 
tissue, is a diverse hormone involved in energy homeostasis and satiety management (Housa 
et al., 2006). Leptin is also produced by the gastric epithelium and we have found that fundic 
levels to be significantly associated with risk of BE (Francois et al., 2008). In esophageal cell 
lines, leptin has been shown to have actions as a growth factor leading to increased 
proliferation (Beales and Ogunwobi, 2007; Lipetz, 1984; Somasundar et al., 2003) and inhibition 
of apoptosis, which may predispose to an increased risk of BE and esophageal 
adenocarcinoma (Beales and Ogunwobi, 2007). These effects have been demonstrated to be 
synergistic when leptin is combined with acid pulses (Beales and Ogunwobi, 2007). The most 
current research has demonstrated a complex signaling pathway by which leptin causes these 
aberrations, however the exact mechanism has not been completely elucidated. It is postulated 
that leptin stimulates a transmembrane leptin receptor, which activates both P38 MAP kinase 
and janus kinase JAK2 pathways. JAK2 also activates P38 MAP kinase, as well as, extracellular 
signal related kinase (ERK) and Akt, which all increase COX-2 mRNA levels. Upregulation of 
COX-2 leads to increased PGE-2 production, which subsequently activates an EP-4 receptor. 
The EP-4 receptor then causes activation of PKC, src, and MMPs, which increase cleavage and 
extracellular shedding of EGFR ligands, HB-EGF and TGFα. These transactivate an epidermal 
growth factor receptor (EGFR) (Beales and Ogunwobi, 2007; Ogunwobi et al., 2006; Ogunwobi 
and Beales, 2008b). Ultimately, C-jun NH2 terminal kinase (JNK) is then activated which leads 
to the inhibition of apoptosis and increased proliferation. It is by this pathway which leptin 
may predispose obese patients to an increased risk of EAC (Beales and Ogunwobi, 2007; 
Ogunwobi et al., 2006).  
Adiponectin is produced solely by white adipose tissue and has been shown to have anti-
atherogenic, anti-inflammatory, and anti-diabetic actions (Housa et al., 2006; Nishida et al., 
2007). It is a protein found in multiple isoforms, high molecular weight (HMW), medium 
molecular weight (MMW), and low molecular weight (LMW) (Suzuki et al., 2007). Unlike 
leptin, adiponectin levels are decreased in obesity, and low levels of adiponectin have been 
associated with an increased risk of BE and EAC (Rubenstein et al., 2008; Yildirim et al., 
2009). Its role in the development of cancer is believed to be protective through anti-
proliferative (Ogunwobi and Beales, 2008a) and pro-apoptotic effects (Konturek et al., 2008). 
Adiponectin leads to a dose-dependent increase in the rate of apoptosis in esophageal 
cancer cell lines, which can be explained by a dose dependent increase and decrease in 
mRNA and protein expression of pro-apoptotic BAX and anti-apoptotic Bcl-2, respectively 
(Konturek et al., 2008). Its anti-proliferative effects may be mediated through its actions on 
adiponectin receptor-1 as well as activation of adenosine monophosphate activated protein 
kinase and serine/threonine phosphatases, which ultimately lead to modulation of p53 and 
p21(Ogunwobi and Beales, 2008a);(Rubenstein et al., 2009). More recent evidence suggests 
unique roles of each adiponectin multimer in the development of BE High levels of LMW 
adiponectin have been shown to be associated with a decreased risk of BE, and conversely, 
high levels of HMW adiponectin are associated with an increased risk (Rubenstein et al., 
2009). LMW adiponectin may prevent the inflammatory reaction of esophageal mucosa by 
suppressing the release of pro-inflammatory interleukin-6 and increasing release of anti-
inflammatory interleukin-10. Therefore, low levels of LMW adiponectin might permit an 
aberrant response to reflux thus leading to metaplastic changes (Schober et al., 2007). Other 
www.intechopen.com
Gastroesophageal Reflux Disease: Molecular 
Predictors in Neoplastic Progression of Barrett’s Esophagus 
 
31 
possible mechanisms of adiponectin that have been postulated include suppression of 
extracellular signal related kinases 1 and 2, which when exuberantly activated lead to 
increased proliferation and decreased apoptosis, and possibly an exacerbated pathologic 
response to reflux (Rubenstein et al., 2008). 
Lastly, ghrelin is a hormone that is produced primarily in the fundus of the stomach, 
(Kojima and Kangawa, 2005) and has a variety of roles which include stimulation of appetite 
as well as gastric acid secretion (Masuda et al., 2000; Wren et al., 2001). Ghrelin levels have 
been shown to be inversely related to adiposity and EAC risk (de Martel et al., 2007), but the 
biomolecular mechanism underlying this association has not been completely elucidated. 
There may be an anti-inflammatory component to the mechanism, as evidence suggests that 
ghrelin inhibits the increased production of COX-2 and interleukin-1β (IL-1β) by tumor 
necrosis factor alpha (TNFα) (Konturek et al., 2008). In addition, ghrelin stimulates gastric 
motility by stimulating the vagus nerve and myenteric neurons. By shortening gastric 
emptying time, this decreases the acid exposure of the lower esophageal and potentially 
decreases the risk of EAC (de Martel et al., 2007).  
By further elucidating the mechanisms behind adipocytokines and their relationships to BE 
and EAC, there may be opportunities for both diagnostic as well as therapeutic approaches 
to these sequelae of GERD. 
5. Microbiome and cancer 
The human body is inhabited by ten times more bacteria than the number of human cells in 
the body (Savage, 1977). The bacteria form ecological communities on every external (skin) 
and internal (mucosal) surfaces of our body. Bacteria in the communities collectively are 
termed by Joshua Lederberg as “microbiome” (Lederberg and McCray, 2001). The host 
relationship with the microbiome can be commensal, symbiotic, and pathogenic. The 
general concept is that the host provides a nutrient-rich habitat, while the bacteria play 
important roles in the development of the mucosal immune system, the maintenance of a 
physiological environment, the provision of essential nutrients, and the prevention of 
colonization by pathogenic bacteria (Cunningham-Rundles et al., 2002; Eckburg et al., 2005). 
On the other hand, certain members of the human microbiome play a pathogenic role, as 
illustrated by traditional medical microbiology built upon concepts of infectious diseases in 
which a pathogen can often be identified and pathogenesis explained by toxins or virulent 
factors produced by the pathogen. These concepts have clearly demonstrated their 
usefulness in the identification of etiologic agents of a number of infectious diseases.  
More recently, the concept that the microbiome is essential for the development of 
inflammation-induced carcinoma has emerged from studies of well-known colonic 
microbiome (Yang and Pei, 2006). In the TCRǃ/p53, IL-10 and Gpx1/Gpx2 knockout mouse 
colitis models that mimic the development of adenocarcinoma in ulcerative colitis, 
carcinoma develops in conventional mice but not in mice raised under germ-free housing 
conditions (Balish and Warner, 2002; Chu et al., 2004; Kado et al., 2001). In IL-10, HLA-
B27/ǃ2m, and TCRǂ knockout mice, the colonic microbiome is also a prerequisite for the 
development of inflammation in the colon (Kawaguchi-Miyashita et al., 2001; Rath et al., 
1996; Sellon et al., 1998; Song et al., 1999). Although intestinal bacteria are an important 
factor in the inflammation and tumorigenesis, their precise role remains elusive. One theory 
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is that both “protective” species and “harmful” species exist within the normal enteric 
microbiome. A healthy balance between these two populations in a normal host might be 
detrimental for an inflammation-prone host. Alternatively, a breakdown in the balance 
between the two populations, termed “dysbiosis”, could by itself promote inflammation in a 
normal host. Chronic inflammation could be carcinogenic. Although resident enteric 
bacteria are necessary for the development of spontaneous colitis in many rodent models, 
not all bacteria have an equivalent capability to induce inflammation. Germ-free IL-10-
deficient mice populated with bacterial strains, including Bacteroides vulgatus, Clostridium 
sordellii, Streptococcus viridans, Escherichia coli, Lactobacillus casei, Lactobacillus reuteri, 
Lactobacillus acidophilus, and Lactobacillus lactis do not exhibit significant colitis (Balish and 
Warner, 2002; Sellon et al., 1998; Sydora et al., 2005). In contrast, Citrobacter rodentium, 
Helicobacter hepaticus, Enterococcus faecalis are examples of conditional cancer-causing 
bacteria that alone do not cause cancer, but are carcinogenic in certain genetically-
engineered immunodeficient mice (Balish and Warner, 2002; Barthold and Jonas, 1977; Engle 
et al., 2002; Erdman et al., 2003; Newman et al., 2001; Sellon et al., 1998; Sydora et al., 2005; 
Ward et al., 1994).  
The observations in rodent models which depict the role of the microbiome in tumorigenesis 
raise some interesting possibilities in relation to human cancers. Although there is no 
established bacterial pathogen for human colorectal cancer, unusual infections might 
precede the clinical diagnosis of cancer. A significant proportion (13%) of patients with 
Streptococcus bovis bacteremia have colon cancer (Panwalker, 1988). In some cases, the 
bacteremia occur months or years before the cancer is diagnosed. Clostridium septicum 
infections are rare, but are often (81%) associated with malignancy including colon cancer 
(34%) (Beebe and Koneman, 1995; Kornbluth et al., 1989).  
The lessons learned from investigations of the colonic microbiome could serve as a general 
guide to studies of the etiology and pathogenesis of chronic inflammatory diseases and 
related cancers in other sites of the gastrointestinal tract. These include conditions such as 
reflux esophagitis and esophageal adenocarcinoma, Helicobacter gastritis and gastric 
adenocarcinoma and lymphoma, as well as inflammatory bowel diseases (IBD) and 
colorectal cancer.  
5.1 Helicobacter pylori as a protective marker for esophageal adenocarcinoma 
Helicobacter pylori is the most established bacterial cause of human cancer. In particular, H. 
pylori causes gastric adenocarcinoma, the fourth most common cancer and second leading 
cause of cancer-related death in the world (Ferlay et al., 2010; Parkin et al., 2005; Peek and 
Blaser, 2002). It is a Gram-negative, microaerophilic bacterium that colonizes the stomach of 
at least half the world's population (Pounder and Ng, 1995). H. pylori causes chronic active 
gastritis and the colonization and inflammation may persist in the stomach for life if not 
treated (Marshall and Warren, 1984). Although most individuals infected by H. pylori are 
asymptomatic, despite having chronic gastritis, approximately 10-20% of the patients will 
develop gastric and duodenal ulcers (Kusters et al., 2006). H. pylori infection is also 
associated with a 1-2% lifetime risk of stomach cancer and a less than 1% risk of gastric 
MALT lymphoma (Kusters et al., 2006). The risk of non-cardia gastric cancer was nearly six 
times higher for H. pylori-infected people than for uninfected people (Webb et al., 2001). In 
1994, the International Agency for Research on Cancer (IARC) classified H. pylori as a group 
1 carcinogen (IARC, 1994). H. pylori infection causes gastric cancer through interaction 
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between bacterial virulent factors and human genes/pathways. H. pylori may directly 
damage the gastric mucosa by bacterial products such as ammonia, phospholipases, and 
toxins and causes mutations by promoting persistent tissue repair and cellular proliferation. 
Secondary response from the host, such as releasing free radicals, reactive oxygen 
metabolites, and cytokines can further damage the gastric mucosa (Bechi et al., 1996). H. 
pylori strains exhibit extensive genetic diversity and strain-specific proteins augment the risk 
for malignancy (Polk and Peek, 2010). Based on the presence or absence of cytotoxin-
associated gene A (cagA), H. pylori can be divided into cagA-positive and cagA-negative 
strains (Covacci et al., 1993; Tummuru et al., 1993). Infection with cagA-positive H. pylori 
strains has been associated with more severe mucosal inflammation, atrophic gastritis and 
increased risk for the development of gastric carcinoma (Blaser et al., 1995; Kuipers et al., 
1995; Parsonnet et al., 1997). There is a twofold increase in the risk of gastric carcinoma 
associated with cagA-positive strains compared to cagA-negative strains (Huang et al., 
2003). H. pylori also augment its carcinogenicity by expression of active vacuolating 
cytotoxin (VacA) as well as blood-group antigen-binding adhesin (BabA1) (Figueiredo et al., 
2002; Louw et al., 2001; Miehlke et al., 2001; Rhead et al., 2007). Eradication of H. pylori leads 
to a modest reduction in gastric cancer risk (Fuccio et al., 2009). On the host side, 
polymorphisms that are associated with increased expression of IL-1ǃ and TNFǂ also 
increases the risk of gastric cancer (El-Omar et al., 2003).  
Paradoxically, H. pylori infection might prevent against the development of EAC. In the 
majority of studies comparing the rates of H. pylori infection in patients with reflux 
disorders, H. pylori infection is associated with a reduced risk of BE and EAC (Islami and 
Kamangar, 2008; Rokkas et al., 2007; Ronkainen et al., 2005; Sorberg et al., 2003; Wang et al., 
2009a). In particular, H. pylori infection is inversely associated with risk for EAC with an 
odds ratio (95% CI) of 0.56 (0.46-0.68), as shown in a meta analysis of 19 case control studies 
(Islami and Kamangar, 2008). The risk reduction is due to infection with CagA-positive 
strains (OR, 0.41; 95% CI, 0.28-0.62) as CagA-negative strains are not protective (OR, 1.08; 
95% CI, 0.76-1.53). H. pylori infection and CagA-positive strains are also associated with a 
reduced risk for EAC in another meta analysis (Rokkas et al., 2007). Similarly, BE is 
inversely correlated with both the H. pylori prevalence (OR, 0.64; 95% CI, 0.43-0.94; P = .025) 
and the prevalence of H. pylori cagA-positive strain (OR, 0.39; 95% CI, 0.21-0.76; P = .005) 
(Rokkas et al., 2007). More recent meta analysis found that the prevalence of H. pylori 
infection is significantly lower in BE than in endoscopically normal healthy controls (23.1% 
vs. 42.7%, OR=0.50, 95% CI 0.27–0.93, P=0.03) but significantly higher in BE patients in 
studies using healthy blood donors as "normal controls" (71.2% vs. 48.1%, OR=2.21, 95% CI 
1.07–4.55). The discrepancy appears to be due to difference in study designs (Wang et al., 
2009a). The healthy blood donors are not appropriate controls because: i). the prevalence of 
H. pylori infection in the blood donors is different from that in the general population 
(Sorberg et al., 2003); ii). Some of the “healthy” blood donors may actually have 
unrecognized BE since they are not examined by endoscopy. BE is present in 1.6% of the 
general Swedish population (Ronkainen et al., 2005).  
Although no simple theory can explain why H. pylori infection reduces the risk of BE and 
EAC, there are several plausible hypotheses. First, H. pylori infection may decrease the tissue 
damage caused by gastroesophageal reflux by lessening the acidity in the refluxate (Ye et al., 
2004). The decrease in gastric acidity could be a result of chronic inflammation and atrophic 
gastritis associated with H. pylori infection as well as the action of bacterial urease that 
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produces ammonia and neutralize gastric acid, independent of gastric atrophy (Richter et 
al., 1998). This hypothesis is consistent with the observed inverse relationship between 
indices of H. pylori infection and occurrence of gastroesophageal reflux symptoms 
(Raghunath et al., 2003). However, simple achlorhydria in patients with pernicious anemia 
does not appears be sufficient for reduction of the risk for EAC, contradicting this 
hypothesis (Ye and Nyren, 2003). Second, H. pylori infection suppresses levels of ghrelin, a 
potent appetite stimulant and potential contributor to obesity (Azuma et al., 2002; Jang et al., 
2008; Nwokolo et al., 2003; Roper et al., 2008; Tatsuguchi et al., 2004; Thrift et al., 2011). 
Because obesity increases the risk for GERD, BE and EAC (Cook et al., 2008; Hampel et al., 
2005; Kubo and Corley, 2006; Whiteman et al., 2008), it is possible that H pylori infection may 
decrease the risks for reflux disorders by reducing body weight. Paradoxically, high ghrelin 
levels (rather than low) reduce the risk for EAC (de Martel et al., 2007). Third, H. pylori is 
capable of inducing esophageal cancer cells to die through apoptosis in vitro experiments, 
which depends on the presence of CagA (Jones et al., 2003). Thus, H. pylori might reduce the 
EAC risk by killing the cancer cells. However, this finding may not be clinically relevant 
because H. pylori does not colonize Barrett’s mucosa (Buttar and Wang, 2004). Ultimately the 
perceived mechanism behind which H. pylori infection may protect against BE and EAC 
remains unclear. 
5.2 Microbiome alteration as a marker for Barrett’s esophagus  
The esophagus, as with other luminal organs of the digestive system, represents a suitable 
environment for bacteria to inhabit. Besides residential bacteria, extraneous bacteria could be 
introduced into the esophagus by swallowing or by reflux from the stomach. However, 
compared with the well-studied colonic and oral microbiomes, characterization of the 
esophageal microbiome has received less attention. Attempts to define the esophageal 
microbiome have been described in 9 reports (Table 1). Previous culture-based studies 
suggested that the esophagus is either sterile or contains only few transient bacteria (Gagliardi 
et al., 1998) but studies (Narikiyo et al., 2004; Pei et al., 2004; Pei et al., 2005; Yang et al., 2009) 
using cultivation-independent PCR have consistently identified indigenous bacteria associated 
with mucosal surfaces in tissue biopsies. Furthermore, the bacteria are visible on the mucosal 
surfaces of the distal esophagus (Figure 1) (Pei et al., 2004). Much of the interest to further 
study of the microbiome comes from its possible link to esophageal disease.  
 
Fig. 1. Visualization of bacteria in the distal esophagus by gram stains in normal.  
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Category 
Culture-based (1981-2007) 
Non-culture-based (2004-2009) 
By Sanger sequencing 
Lau 
1981 
Finlay 
1982 
Mannell 
1983 
Gagliardi
1998 
Macfarlane
2007 
Narikiyo 
2004 
Pei 
2004 
Pei 
2005 
Yang 
2009 
Disease Cancer Cancer Cancer Normal BE Cancer Normal
RE,  
BE 
RE, BE, 
Normal 
Specimen Aspirate Resection Aspirate Aspirate
Biopsy 
Aspirate
Biopsy Biopsy Biopsy Biopsy 
No. cases 79 12 101 30 14 20 4 24 34 
No. isolates or 
clones 
61 85 377 30 ND 100 900 147 6,800 
No. species 14 15 32 11 46 7 95 39 166 
Mean species per 
case 
1 6 4 1 ND ≤6 43 ND 24.7 
% cases positive for 
bacteria 
64 100 100 67 71 ND 100 100 100 
% cases positive for 
Streptococcus 
10 92 ND ND 50 87 100 ND 100 
Table 1. Summary of culture-based and non-culture-based studies on bacterial biota of the 
esophagus 
A recent study of human distal esophagus microbiome (Yang et al., 2009) linked inflammation 
and BE to the change in the microbiome. The study used 16S rRNA gene survey to 
characterize the bacterial communities in biopsy samples taken from the distal esophagus of 34 
individuals with either normal mucosa (n=12), esophagitis (n=12), or BE (intestinal metaplasia) 
(n=10). Two hundred 16S rRNA genes were cloned and sequenced from each sample. Overall, 
the 6800 sequences represented 9 phyla, 70 genera, or 166 species. Firmicutes is the only 
phylum consistently detected in all 34 samples, whereas the other 8 phyla, Bacteroidetes, 
Proteobacteria, Actinobacteria, Fusobacteria, TM7, Spirochaetes, Cyanobacteria and 
unclassified bacteria were less common. The samples from healthy subjects were dominated 
by streptococci. On average, 76% of the sequences from healthy esophageal mucosa were 
categorized to belong to streptococcal species and the numbers of some other species were low, 
but significantly increased in reflux esophagitis and BE.  
With an unsupervised approach, samples of the microbiome form two distinct clusters or 
two microbiome types, type I and II (Figure 2), based on combined genetic distance between 
samples. Although neither of the two types of microbiome exclusively correlated with the 3 
phenotypes, the type I microbiome is more closely associated with normal esophagus 
(11/12, 91.7%), whereas the type II microbiome is mainly associated with abnormal 
esophagus (13/22, 59.1%) (p=0.0173 among group comparison), including both esophagitis 
(7/12, 58.3%, OR=15.4) and BE (6/10, 60.0%, OR=16.5) (Table 2). The alteration of 
microbiome from type I to type II in distal esophagus, thus, is associated with host 
phenotypes and its disease progression.  
Streptococcus is the most dominant genus in the esophageal microbiome and its relative 
abundance differs between the two types of microbiome and decreases in disease states. 
Overall, the 20 type I samples had a mean of 78.8% Streptococcus (range, 60.5%–97.0%), 
whereas the 14 type II samples had a mean of 30.0% (range, 8.0%– 46.5%) (P < 1x10-10). The 
mean of relative abundance of Streptococcus in the normal esophagus group (75.9%) was 
significantly higher than that in the esophagitis (50.5%) and BE (54.1%) groups (Table 3) 
(Figure 3).  
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Fig. 2. Typing of esophageal microbiome. Detection of natural microbiome groups by 
unsupervised cluster analysis. The dendrogram was constructed using the average linkage 
algorithm and cosine measure of the genetic distance calculated from samples of the 
microbiome. Samples are represented by colored rectangles (green for normal, red for 
esophagitis, and black for Barrett’s esophagus).  
 
Omnibus testA 
Groups compared 
Phenotype 
Normal Esophagitis BEB 
Microbiome 
type 
I 11 5 4 
II 1 7 6 
P value 0.0173 
Follow-up testsC 
Groups compared 
Phenotype 
Normal Esophagitis Normal BE Esophagitis BE 
Microbiome 
type 
I 11 5 11 4 5 4 
II 1 7 1 6 7 6 
P value 0.027* 0.020* 1.000 
Odds ratio 
(95% C.I.) 
15.4 
(1.5-161.0) 
16.5 
(1.5-183.1) 
1.1 
(0.2-5.9) 
A The Omnibus test was performed using the two-tailed Fisher-Freeman-Halton 3 x 2 probability 
test. 
B BE, Barrett’s esophagus. 
C The follow-up tests were performed with the two-tailed Fisher exact 2 x 2 probability test. 
Tests that are statistically different at the false discovery rate < 5% 21 are marked by *.
Table 2. Association between host phenotypes and microbiome types in the distal esophagus 
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Fig. 3. Taxonomic definition of microbiome types. Classification of microbiome by the 
relative abundance of Streptococcus. An outlier (solid circle) was excluded using a box plot in 
which the upper whisker length is 1.5*IQR. The 95% normal reference range (NRR) (mean ± 
1.96 S.D.) was calculated by the relative abundance of Streptococcus after excluding the 
outlier. The dotted line (50.3%) is the upper limit of the 95% normal reference range (NRR), 
which separates the 34 samples into normal (inside the NRR) and abnormal taxonomic types 
(outside the NRR). 
Omnibus testa 
Groups compared
Phenotype 
Normalb 
(n=11) 
Esophagitis 
(n=12) 
BE 
(n=10) 
Relative 
abundance (%) 
75.9 50.5 54.1 
P value 0.043 
Follow-up testsc 
Groups compared
Phenotype 
Normal Esophagitis Normal BE Esophagitis BE 
Relative 
abundance (%) 
75.9 50.5 75.9  50.5 54.1 
P value 0.016* 0.029* 0.773 
a The Omnibus test was performed using one-way ANOVA. 
b An outlier (E15) in the normal group was not included in comparisons between esophageal 
phenotypic groups. 
c The follow-up tests were performed with two-tailed independent t-test. Tests that are statistically 
different at the false discovery rate < 5% are marked by *. 
Table 3. Comparisons of histological phenotypes in relative abundance of Streptococcus 
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In the disease-associated type II microbiome, the decrease in the relative abundance of 
Streptococcus is compensated by an increase in the relative abundance of 24 other genera. 
Specifically, the most prominent increase involves Veillonella, Prevotella, Haemophilus, 
Neisseria, Rothia, Granulicatella, Campylobacter, Porphyromonas, Fusobacterium, and 
Actinomyces, many of which are Gram-negative anaerobes or microaerophiles and are 
putative pathogens for periodontal disease. Anaerobic (type I: 11.0% vs. type II: 38.2%, P = 
1.2 x 10-5) and microaerophilic bacteria (5.4% vs. 23.0%, p= 1.1 x 10-4) are more abundant in 
the type II microbiome than in the type I microbiome (Figure 4A). Gram-negative bacteria 
comprise 53.4% of type II microbiome but only 14.9% of type I microbiome (p= 8.0 x 10-10) 
(Figure 4B). Overall, the type II microbiome is significantly more diverse (Shannon-Wiener 
diversity index mean of 2.69 vs. 1.51, P = 1.3 x 10 -7) and more even (Shannon-Wiener 
evenness index mean 0.78 vs. 0.51, P = 4.2 x 10-8) than the type I microbiome (Figure 5).  
 
Fig. 4. Taxonomic characterization of microbiome by population of main bacterial groups. 
Comparisons of microbiome types according to culture conditions (Panel A) and staining 
properties (Panel B). 
 
Fig. 5. Difference between the 2 types of microbiome in biologic diversity. (A) Shannon-
Wiener diversity index. (B) Shannon-Wiener evenness index. (C) Richness by observed and 
estimated SLOTUs (Chao, 1984). Mean ± 1.96 SD is indicated by horizontal lines.  
The type II microbiome appears to be the strongest (OR >15) amongst all known 
environmental factors that are associated with the pathological changes related to 
gastroesophageal reflux (Table 4). This finding has opened a new approach to  
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Category Subcategory Predictive factor 
Predicted 
outcome 
(defining 
method) 
Sample 
size 
Odds 
ratio 
95% C.I. Reference 
Host 
Genetic 
Immediate relatives 
Heartburn 
(questionnaire)
1,524 2.6 1.8-3.7 Locke, 1999 
Parental family history 3,920 1.5 1.2-1.7 
Mohammed, 
2005 
Aging Increasing age GERD (ICD-9 
code) 
163,085
1.1 1.0-1.1 
Kotzan, 2001 
Structural 
Hiatus hernia 
4.2 2.8-6.3 
BE (histology) 457 3.9 2.5-6.0 
Conio, 2001 Esophagitis 
(endoscopy) 
451 2.4 1.5-4.0 
Papillae elongation 
Heartburn 
(medical 
record) 
1,128 2.2 1.5-3.2 
Voutilainen, 
2000 
Symptomatic Heartburn/regurgitation
Esophagitis 
(endoscopy) 
451 9.4 6.1-14.4 Ruigomez, 
2004 
BE (histology) 457 5.8 4.0-8.4 
Comorbid 
Gallbladder disease 
GERD (ICD-8 
codes) 
7,451 3.7 2.1-6.7 
Ruigomez, 
2004 
Asthma 
GERD (ICD-9 
code) 
163,085 3.2 2.6-4.0 Kotzan, 2001 
Angina 
GERD (ICD-8 
codes) 
7,451 3.2 2.1-4.9 
Ruigomez, 
2004 
Obesity 
GERD (ICD-9 
code) 
163,085 2.8 2.1-3.6 Kotzan, 2001 
Peptic ulcer disease 
GERD (ICD-8 
codes) 
7,451 
2.5 1.7-3.6 
Ruigomez, 
2004 
Chest pain 2.3 1.8-2.8 
Cough 1.7 1.4-2.1 
Irritable bowel syndrome 1.6 1.2-2.1 
Environment 
Behavioral 
Tobacco 
GERD (ICD-9 
code) 
163,085
2.6 1.9-3.5 
Kotzan, 2001 Alcohol 1.8 1.4-2.4 
Medical 
NSAID 1.8 1.6-2.1 
Anticholinergic drug 
Heartburn 
(questionnaire)
3,920 1.5 1.1-2.1 
Mohammed, 
2005 
Nitrates GERD (ICD-8 
codes) 
7,451 
1.5 1.1-2.0 Ruigomez, 
2004 Oral steroids 1.3 1.1-1.6 
Bacterial Type II microbiome 
Esophagitis 
(histology) 
24 15.4 1.5-161.0 
Yang, 2009 
BE (histology) 22 16.5 1.5-183.1 
NSAID: Nonsteroidal anti-inflammatory drug. 
GERD: gastroesophageal reflux disease. 
BE: Barrett’s esophagus. 
ICD: international classification of diseases. 
ICD-8 codes for GERD: gastroesophageal reflux, esophagitis, esophageal inflammation, or heartburn. 
ICD-9 code for GERD: not specified in detail.
Table 4. Comparison of the type II microbiome with known risk factors in gastroesophageal 
reflux disorders 
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understanding the recent surge in the incidence/prevalence of GERD, BE and EAC, and 
suggest the possible role of dysbiosis in their pathogenesis. The diverse type II community 
with its larger content of Gram-negative bacteria might engage innate immune functions of 
the epithelial cells in a different way than the type I microbiome, owing to the release of a 
larger spectrum of microbial components, such as lipopolysaccharide (LPS) of Gram-
negative bacteria stimulating pattern receptors (eg, Toll-like receptors). Furthermore, the 
type II microbiome that contains significant numbers of potential pathogens, such as 
Campylobacter, Veillonella, Prevotella, Haemophilus, Neisseria, Porphyromonas, Fusobacterium, and 
Actinomyces and a significantly higher percentage of Gram-negative bacteria, might play a 
role with relevance in the maintenance of inflammation. On the other hand, the type II 
microbiome might be secondary to changes caused by gastric reflux. The type I microbiome 
could represent a direct extension of the normal oral microbiome via saliva while the type II 
microbiome could represent regurgitated bacteria in gastric juice or a microbiome modified 
gastric acid by selecting against acid-sensitive bacteria in the esophagus. However, at this 
stage, it is unclear whether the presence of type II microbiome (or the absence of type I 
bacteria) plays a causal role in the pathogenesis of esophageal inflammation or BE. These 
hypotheses will have to be addressed by future studies, which should be conducted with a 
prospective design and involve a finer characterization of the microbiomes (Suerbaum, 
2009). The microbiome alteration from type I to type II might prove to be an important step 
in the pathogenesis of esophageal tumorigenesis, and represent a biologically more 
plausible microbial component in GERD-BE-EAC progression. Consequently, it is essential 
to assess the type II microbiome and/or numbers of its potential pathogens as either a sole 
or a panel of biomarkers in order to decipher its relevance in GERD-BE-EAC progression.  
6. Prognostic value of biomarkers 
As discussed, biomarkers have an important role during the transition of BE to EAC. 
However, the diagnosis of dysplasia is still the principal marker that is monitored by 
endoscopic surveillance biopsies, with the aim of intervening prior to invasive 
adenocarcinoma. The shortcomings of this algorithm include undiagnosed disease, an 
unproven reduction in population mortality, and unnecessary surveillance. In addition, the 
current staging of EAC is based exclusively on the anatomical extent of the disease, and the 
tumor depth (T), lymph nodes involved (N), and the presence or absence of metastases (M); 
the TNM system. Despite the great number of relevant biomarkers that have been described, 
none are yet incorporated in a clear prognostic model in EAC. Much investigation is 
currently underway to identify prognostic biomarkers that may determine the best 
therapeutic course in this disease. 
The development of cancer is generally accepted as being categorized by essential 
alterations in cell physiology that, when combined, dictate neoplasia: self-sufficiency in 
growth signals, insensitivity to antigrowth signals, evasion of apoptosis, limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis (Hanahan and 
Weinberg, 2000). For EAC, each of these physiologic changes is associated with relevant 
biomarkers that have been examined for prognostic potential. Two recent reviews detail the 
prognostic evidence of biomarkers by using these categories of mechanisms (Lagarde et al., 
2007; Ong et al., 2010). 
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Several biomarkers are known to enable self-sufficiency in growth signals, and could have a 
vital impact on the different phenotypes of EAC. In a study of 124 EAC specimens, two of 
three specific genotypes of cyclin D1 were found to be predictive of overall survival time 
(Izzo et al., 2007). In addition, several studies have looked at the prognostic relevance of EGF 
and TGF-ǂ, two growth factors that bind to the EGFR. TGF-ǂ protein expression has been 
shown to be significantly associated with tumor progression and lymph node metastasis 
(D'Errico et al., 2000). Alternatively, in patients with node-negative esophageal cancer, low-
level expression of TGF-ǂ is associated with a worse prognosis (Aloia et al., 2001). These 
apparently conflicting findings are further complicated by studies of EGFR expression in 
EAC specimens, as one study showed a trend in its multivariate analysis towards expression 
and decreased survival, (Wang et al., 2007) and another showed significantly poorer 
survival in association with decreased expression in a univariate analysis (Langer et al., 
2006). The mechanisms behind these seemingly discordant findings of the expression of 
EGFR and its related growth factors are yet to be elucidated. Furthermore, an oncogene 
HER-2/neu related to EGFR has been shown to significantly correlate with poorer survival 
in EAC, and may have independent prognostic significance (Brien et al., 2000). 
Other biomarkers are thought to act in progression of EAC by insensitivity to growth-
inhibitory signals, including TGF-ǃ and APC. For TGF-ǃ, there is some correlation on 
univariate analysis that overexpression of the gene is associated with depth of tumor 
infiltration, nodal involvement, and lymphatic vessel invasion, in addition to having a 
significant negative impact on survival (von Rahden et al., 2006). This evidence was 
reinforced in a intraoperative study of the mean levels of TGF-ǃ1 from the azygos vein in 
patients with esophageal cancer, as higher levels significantly correlated with poorer 
survival. However, the majority of these cancers were esophageal squamous cell carcinoma, 
as opposed to adenocarcinoma (Fukuchi et al., 2004). The APC gene, a biomarker well 
known for its relationship with colon adenocarcinoma, has also been studied in esophageal 
carcinomas. One study found a dramatic and significant increase in the methylation of APC 
DNA in the plasma of patients with EAC, and this was associated with reduced patient 
survival (Kawakami et al., 2000).  
Other potential predictive biomarkers in EAC are those that affect cell cycle arrest and the 
evasion of apoptosis. Immunohistochemical expression of both P21 and P53 have been 
studied in patients with EAC before and after treatment with chemotherapy. Some data 
suggests that loss of P53, surprisingly, and gain in expression of P21 have both correlated 
with better response to chemotherapy and survival (Heeren et al., 2004). The Bcl-2 family of 
genes have been well studied as apoptotic regulators of programmed cell death in several 
malignancies. In EAC, data show that expression of Bcl-2 is ultimately associated with 
improved survival, but does not predict response before neoadjuvant chemotherapy, 
suggesting a reliance on other factors in guiding response to this therapy (Raouf et al., 2003). 
Furthermore, NF-κǃ, presumably by involvement in apoptosis, has been shown in a study of 
esophageal carcinoma specimens, with the vast majority being adenocarcinoma, to be 
activated and then significantly associated with overall and disease free survival after 
chemotherapy (Izzo et al., 2006). 
The expression of COX-2, a marker of induction of apoptosis as well as increased 
angiogenesis, has shown promise in predicting prognosis in EAC. An original study of the 
intensity of immunohistochemical staining for COX-2 in EAC specimens revealed a 
www.intechopen.com
 
Gastroesophageal Reflux Disease 
 
42
significant association of higher COX-2 expression and amount of distant metastases, local 
recurrences, and decreased survival (Buskens et al., 2002). Poorer survival with increased 
COX-2 expression was substantiated in a smaller study of specimens from patients who 
underwent esophagectomy and either died within one year, or survived three years (France 
et al., 2004). Finally, a later study of 100 surgically resected specimens of EAC showed 
significant correlation of COX-2 expression and higher T stage, N stage, risk of tumor 
recurrence, and overall decreased survival (Bhandari et al., 2006).  
Another mechanism thought necessary for neoplastic transformation is the acquisition of 
limitless replicative potential, as tumors stabilize their telomeres and halt the limited 
number of pre-defined cell divisions before growth arrest. In a study of 46 patients with 
resection of Barrett’s related esophageal adenocarcinoma, telomere length was studied by 
Southern blot analysis. The telomere-length ratio of neoplastic to normal tissue was 
correlated with overall survival, as patients with higher ratios had significantly poorer 
survival (Gertler et al., 2008). 
Angiogenesis is another necessary capability of malignant tumors, and its development has 
also been studied in regards to prognosis of EAC. CD105, or endoglin, as well as VEGF are 
both known factors that perform a major role in angiogenesis. In a study of 75 patients and 
specimens from esophagectomies to treat adenocarcinoma, endoglin or VEGF staining of 
microvessels was used to account for angiogenesis. Both endoglin and VEGF showed a 
prognostic significance and positive correlation with angiolymphatic invasion, lymph node 
metastases, and poorer survival (Saad et al., 2005). 
The last classic mechanism thought to be vital for neoplastic transformation is tissue invasion 
and metastasis. Potential prognostic biomarkers involved in this invasion in EAC include the 
cell adhesion molecule E-cadherin, as well as uPA and TIMP-3, proteins involved in breaking 
down or preserving the extracellular matrix, respectively. Reduced levels of E-cadherin, by 
immunohistochemical staining of 59 Barrett’s related esophageal adenocarcinoma specimens, 
was associated with significantly poorer prognosis (Falkenback et al., 2008). By also 
contributing to invasiveness of tumor cells, higher uPA expression was shown to be correlated 
with poorer survival, and correspondingly, in another study loss of TIMP-3 correlated with 
poorer survival and higher disease stage (Darnton et al., 2005; Nekarda et al., 1998). 
Several of the aforementioned biomarkers are promising in deciphering prognosis in EAC, 
and show an association with tumor invasiveness or patient survival. However, the 
evidence for each individual marker has typically not been well replicated, and molecularly 
it is unlikely that any of these markers can correctly predict survival on their own, as many 
of the alterations are related. More recently, microarray technology has allowed for 
molecular signatures that examine several targets simultaneously. This is a rapidly evolving 
area of research, and several studies have already examined molecular signatures in EAC in 
order to attempt to accurately prognosticate. 
The studies using microarray technology to generate molecular prognostic signatures for 
EAC have also attempted to externally validate their findings. One study on 75 resected 
esophageal specimens generated a set of four genes found to be prognostic at the protein 
level, which allows for more clinical applicability. This molecular signature was found to be 
significantly predictive of survival based on the amount of genes dysregulated, and was 
externally validated in a cohort of 371 cases (Peters et al., 2010). Other studies have not 
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shown such promising results, as a study attempting to generate a prognostic gene 
expression profile for lymphatic dissemination in EAC was unsuccessful, but did identify an 
importance of argininosuccinate synthetase (ASS) in the development of this lymphatic 
dissemination (Lagarde et al., 2008). Microarray technology has also shown its potential for 
unexpected, though potentially important, results. In looking at response to neoadjuvant 
chemotherapy in EAC with microarray technology, one study showed a total of 86 genes 
that were differentially regulated , with the strongest difference in gene expression found 
with the gene encoding the ephrin B3 receptor, a tyrosine kinase receptor primarily 
described in the nervous system (Schauer et al., 2010). 
In addition to the above methods of microarray technology, other approaches have been 
used to develop molecular signatures important in the prognosis of EAC. One study used 
protein expression profiling on 34 patients who underwent surgical resection for locally 
advanced EAC, and found a significant association between decreased expression of a 
particular protein, heat shock protein 27 (HSP27), and nonresponse to neoadjuvant 
chemotherapy. As overexpression of HSP27 has been shown to be associated with resistance 
to chemotherapy in several other cancers, including esophageal squamous cell carcinoma, 
this is a novel finding that needs to be further studied (Langer et al., 2008). Another study 
looked at a panel of genetic polymorphisms on survival outcomes in 210 esophageal 
carcinoma patients treated with fluorouracil, with 83% having adenocarcinoma. The study 
found five polymorphisms in three genes significantly associated with decreased 
recurrences and related disease free survival (Wu et al., 2006). Yet another study analyzed 
microRNA expression in 100 EAC patients, and found that reduced levels of microRNA-375 
was associated with worse survival, suggesting a need for further study of microRNAs in 
the prognosis of this disease (Mathe et al., 2009). Finally, in a novel study looking at the total 
number of chromosomal aberrations in specimens of EAC using a multiplex ligation-
dependent probe amplification technique, a significant negative correlation between patient 
survival and total number of aberrations was found. This finding may provide a more 
general, but still important, indicator of disease outcome (Pasello et al., 2009). 
7. Conclusion 
Overall, a lot of interest has been given to the study of biomarkers in EAC development, and 
to both identify prognostic indicators as well as guide therapy. Despite the large number of 
researched biomarkers showing a correlation with survival in EAC, it is unlikely that a 
single biomarker will adequately predict prognosis and survival in this disease. The wealth 
of data using traditional methods, in conjunction with new technologies geared towards 
molecular signatures, have identified both individual and panels of biomarkers important in 
predicting neoplastic transformation. However large-scale prospective cohorts are still 
needed to validate these biomarkers or molecular/microbiome signatures in development. 
Ultimately, these prognostic biomarkers will hopefully be incorporated into a model that 
can help with clinical management of patients with EAC. 
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